Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S, ESMO Guidelines Committee (2018) Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv192–iv237. https://doi.org/10.1093/annonc/mdy275

Article  CAS  PubMed  Google Scholar 

Tian HX, Zhang XC, Yang JJ, Guo WB, Chen ZH, Wang Z, Wu YL (2017) Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients. Lung Cancer 114:90–95. https://doi.org/10.1016/j.lungcan.2017.11.001

Article  PubMed  Google Scholar 

Chen J, Xu C, Lv J, Lu W, Zhang Y, Wang D, Song Y (2023) Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review. Transl Lung Cancer Res 12(4):895–908. https://doi.org/10.21037/tlcr-22-566

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385–2394. https://doi.org/10.1056/NEJMoa1214886

Article  CAS  PubMed  Google Scholar 

Hirota T, Muraki S, Ieiri I (2019) Clinical pharmacokinetics of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer. Clin Pharmacokinet 58(4):403–420. https://doi.org/10.1007/s40262-018-0689-7

Article  CAS  PubMed  Google Scholar 

Zia V, Lengyel CG, Tajima CC, de Mello RA (2023) Advancements of ALK inhibition of non-small cell lung cancer: a literature review. Transl Lung Cancer Res 12(7):1563–1574. https://doi.org/10.21037/tlcr-22-619

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Gao M, Tong M, Xie C, He Y, Fu L, Li Y, Fu H, Lou L (2018) Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met. Am J Cancer Res 8(8):1541–1550

CAS  PubMed  PubMed Central  Google Scholar 

Ma Y, Zhao H, Xue J, Liu L, Yang N, Zhang Y, Yang H, Hong S, Xiong Y, Zhang Z, Zeng L, Pan H, Zhou C, Zhang Y, Wang X, Han X, Wan X, Shao Y, Liu J, Yang Y, Huang Y, Zhao Y, Fang W, Li S, Zhang L (2022) First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. Eur J Cancer 173:238–249. https://doi.org/10.1016/j.ejca.2022.06.037

Article  CAS  PubMed  Google Scholar 

Yang Y, Min J, Yang N, Yu Q, Cheng Y, Zhao Y, Li M, Chen H, Ren S, Zhou J, Zhuang W, Qin X, Cao L, Yu Y, Zhang J, He J, Feng J, Yu H, Zhang L, Fang W (2023) Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial. Signal Transduct Target Ther 8(1):301. https://doi.org/10.1038/s41392-023-01538-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hop CE, Wang Z, Chen Q, Kwei G (1998) Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87(7):901–903. https://doi.org/10.1021/js970486q

Article  CAS  PubMed  Google Scholar 

Penner N, Klunk LJ, Prakash C (2009) Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos 30(4):185–203. https://doi.org/10.1002/bdd.661

Article  CAS  PubMed  Google Scholar 

Johnson TR, Tan W, Goulet L, Smith EB, Yamazaki S, Walker GS, O’Gorman MT, Bedarida G, Zou HY, Christensen JG, Nguyen LN, Shen Z, Dalvie D, Bello A, Smith BJ (2015) Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. Xenobiotica 45(1):45–59. https://doi.org/10.3109/00498254.2014.941964

Article  CAS  PubMed  Google Scholar 

Tan W, Yamazaki S, Johnson TR, Wang R, O’Gorman MT, Kirkovsky L, Boutros T, Brega NM, Bello A (2017) Effects of renal function on crizotinib pharmacokinetics: dose recommendations for patients with ALK-positive non-small cell lung cancer. Clin Drug Investig 37(4):363–373. https://doi.org/10.1007/s40261-016-0490-z

Article  CAS  PubMed  Google Scholar 

Zhou S, Liu W, Zhou C, Zhang L, Xie L, Xu Z, Wang L, Zhao Y, Guo L, Chen J, Ding L, Mao L, Tao Y, Zhang C, Ding S, Shao F (2020) Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. Cancer Chemother Pharmacol 86(6):719–730. https://doi.org/10.1007/s00280-020-04159-0

Article  CAS  PubMed  Google Scholar 

Morcos PN, Yu L, Bogman K, Sato M, Katsuki H, Kawashima K, Moore DJ, Whayman M, Nieforth K, Heinig K, Guerini E, Muri D, Martin-Facklam M, Phipps A (2017) Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects. Xenobiotica 47(3):217–229. https://doi.org/10.1080/00498254.2016.1179821

Article  CAS  PubMed  Google Scholar 

Hsu JC, Carnac R, Henschel V, Bogman K, Martin-Facklam M, Guerini E, Balas B, Zeaiter AH, Phipps A, Morcos PN, Frey N (2016) Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population. J Clin Oncol 34(15_suppl):e20598–e20598. https://doi.org/10.1200/JCO.2016.34.15_suppl.e20598

Article  Google Scholar 

Gupta N, Wang X, Offman E, Prohn M, Narasimhan N, Kerstein D, Hanley MJ, Venkatakrishnan K (2021) Population pharmacokinetics of brigatinib in healthy volunteers and patients with cancer. Clin Pharmacokinet 60(2):235–247. https://doi.org/10.1007/s40262-020-00929-4

Article  CAS  PubMed  Google Scholar 

Lin S, Gong J, Canas GC, Winkle P, Pelletier K, LaBadie RR, Ginman K, Pithavala YK (2022) A phase I study to evaluate the pharmacokinetics and safety of lorlatinib in adults with mild, moderate, and severe renal impairment. Eur J Drug Metab Pharmacokinet 47(2):235–245. https://doi.org/10.1007/s13318-021-00747-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stypinski D, Fostvedt L, Lam JL, Vaz A, Johnson TR, Boerma JS, Pithavala YK (2020) Metabolism, excretion, and pharmacokinetics of lorlatinib (PF-06463922) and evaluation of the impact of radiolabel position and other factors on comparability of data across 2 ADME studies. J Clin Pharmacol 60(9):1254–1267. https://doi.org/10.1002/jcph.1621

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration (2016) Safety testing of drug metabolites, guidance for industry. https://www.fda.gov/media/72279/download. Accessed March 2020

US Food and Drug Administration (2003) Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. https://www.fda.gov/media/71311/download. Accessed May 2003